This study provides a novel experimental design approach for refractory tunnel lesions in hidradenitis suppurativa, suggesting that when single-target efficacy is limited, priority should be given to exploring bispecific antibody strategies targeting spatially co-localized pathways.
Literature Overview
The article titled 'Targeting an IL-17/IL-36 pathogenic hub in hidradenitis suppurativa with a bispecific antibody', published in 'Signal Transduction and Targeted Therapy', systematically explores the molecular mechanisms of tunnel lesions in hidradenitis suppurativa (HS) and the efficacy of the novel bispecific antibody HB0043. By integrating multi-omics analyses, the study reveals the synergistic interaction between the IL-17 and IL-36 pathways within the tunnel microenvironment and validates the significant advantages of simultaneously blocking these two pathways in both preclinical and early-phase clinical trials.Background Knowledge
Hidradenitis suppurativa (HS) is a chronic, debilitating inflammatory skin disease. Its core challenge lies in the formation of deep epithelialized dermal tunnels, which act as persistent reservoirs of inflammation, making anatomical healing difficult to achieve with traditional single-target biologics (e.g., anti-TNF-α, anti-IL-17A). Current monotherapies targeting either the IL-17 or IL-36 pathways show limited efficacy in tunnel regression, primarily due to the failure to capture the complex cellular interaction networks within the lesions. This study leverages spatial transcriptomics to precisely identify migration-specific spinous keratinocytes (spinous-mig) unique to tunnels. These cells exhibit high expression of IL-36γ and high sensitivity to IL-17A signaling, revealing the spatial co-enrichment and functional synergistic amplification of IL-17A and IL-36γ. This discovery provides a solid biological foundation for developing dual-target blockade strategies.
Research Methods and Core Experiments
The authors first employed single-cell RNA sequencing (scRNA-seq) combined with spatial transcriptomics (ST-seq) to conduct high-resolution analyses of lesional skin from 11 HS patients and healthy controls, successfully identifying tunnel-specific cell subpopulations and their spatial distribution characteristics. Subsequently, in vitro co-culture experiments verified the synergistic stimulatory effects of IL-17A and IL-36γ on keratinocyte proliferation and inflammatory cytokine secretion. Building on this, the research team developed the bispecific antibody HB0043 targeting IL-17A and IL-36R, demonstrating in vitro that its anti-inflammatory capacity surpasses that of monoclonal antibodies and anti-IL-17A/IL-17F bispecific antibodies. Finally, a proof-of-concept clinical trial (NCT06895499) was conducted involving 15 patients with severe HS. High-frequency ultrasound was used to objectively assess tunnel changes, while plasma proteomics dynamically monitored systemic inflammation and metabolic status.Key Conclusions and Perspectives
Research Significance and Prospects
This discovery holds major implications for drug development, indicating that for complex inflammatory diseases, designing bispecific antibodies capable of targeting spatially co-localized pathways is a key strategy to break through the efficacy ceiling of monotherapy. In terms of clinical monitoring, the study emphasizes the importance of using imaging modalities such as ultrasound to assess changes in deep tunnel structures, which better reflects anatomical healing than clinical scores alone. Furthermore, this study offers a new paradigm for disease modeling, suggesting that future animal model construction should focus more on epithelial-mesenchymal interactions and the spatial microenvironment of specific cell subpopulations to better simulate refractory human lesions.
Conclusion
By integrating multi-omics technologies with clinical translational validation, this study has fundamentally transformed our understanding of the mechanisms underlying tunnel lesions in hidradenitis suppurativa, redefining them as spatially ordered inflammatory hubs driven synergistically by IL-17A and IL-36γ. The success of HB0043 not only demonstrates the immense potential of bispecific antibodies in tackling refractory hidradenitis suppurativa but also provides a replicable therapeutic paradigm for other autoimmune diseases with complex microenvironments. From mechanistic elucidation in the laboratory to structural healing in the clinic, this research marks a significant leap in HS treatment from mere symptom control to deep tissue repair, laying a solid foundation for establishing a more precise care system for related diseases in the future.
